Alluvi, formerly BI 4744, presents a promising advance in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates remarkable https://letsbookmarkit.com/story22100451/alluvi-a-detailed-examination-into-the-drug-s-potential